Dr. Fred Eshelman is a Co-Founder of ARC Therapeutics and serves as its Chairman. He served as a Board Member of Meryx. He serves as Chairman at Cellective BioTherapy and Aravive Inc. He is the founder of Eshelman Ventures. He also served as Co-Chairman at Asepticys. He also serves as Chairman at Eyenovia. He also is an Angel Investor. Dr. Eshelman served as Chief Executive Officer and Board Member at Innocrin Pharmaceuticals. Mr. Eshelman served as Advisor at Auven Therapeutics. He also serves as Board Member at G1 Therapeutics, Eyenovia, Innocrin Pharmaceuticals, Fount Therapeutics. Mr. Eshelman was previously the Founding Chairman at Furiex Pharmaceuticals and also served as Executive Chairman and CEO at Pharmaceutical Product Development. He also serves as Executive Chairman at The Medicines Company where he formerly served as a Non-Executive Chairman. Dr. Eshelman has received many awards including the Davie and Distinguished Service Awards from UNC and Outstanding Alumnus from both the UNC and University of Cincinnati schools of pharmacy, as well as the NC Entrepreneur Hall of Fame Award. He has received the doctor of pharmacy from the University of Cincinnati, completed a residency at Cincinnati General Hospital, and a BS in pharmacy from UNC-CH. He is a graduate of the OPM program at Harvard Business School. He also serves as the Board Member at Aeromd.